Immunic adds Elena Ridloff to board ahead of Phase 3 MS readout

Immunic, Inc. (Nasdaq: IMUX) said on August 10, 2026 that it had appointed Elena Ridloff, CFA to its board of directors, effective August 6, 2026. The board appointed her as a Class I director, with a term lasting until the company's 2027 annual meeting of stockholders.¹

Ridloff has served as Chief Financial Officer of Sionna Therapeutics, Inc., a publicly traded life sciences company, since September 2021.¹ She previously served as Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc., joining ACADIA in April 2018 as Senior Vice President, Investor Relations, and serving as CFO from October 2018 to September 2021.¹ Before ACADIA, she held roles at Alexion Pharmaceuticals, Inc., including Executive Director, Investor Relations from April 2014 to January 2016, and Vice President, Investor Relations from January 2016 to March 2018.¹ She also spent over a decade as an institutional investor, serving from July 2005 to January 2012 as Managing Director at Maverick Capital, a hedge fund, where she was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors.¹ She has served on the board of directors of Kymera Therapeutics, Inc. since March 2021,¹ and from September 2020 until its acquisition by Concentra Biosciences, LLC in June 2025, she served on the board of Kronos Bio, Inc.¹

In connection with her appointment, Ridloff received an option grant for up to 50,740 shares of common stock, effective August 6, 2026, vesting monthly over three years, with an exercise price equal to the August 6, 2026 closing price.¹

Separately, the filing detailed terms for Daniel Vitt, who resigned from the board on August 6, 2026¹. On August 7, 2026, the company entered a Separation Agreement under which his employment ended, and he agreed to serve as Chair of the company's Scientific Advisory Board.¹ Severance includes a lump-sum payment of $670,000 covering twelve installments, plus an aggregate bonus of $276,375, with additional payments over 16.5 months.¹

Immunic's lead program, vidofludimus calcium, has top-line Phase 3 data expected by the end of 2026, with an additional Phase 3 trial in progressive MS expected to begin later in 2026.¹